Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.16M Buy
4,609
+487
+12% +$105K 0.72% 36
2026
Q1
$896K Buy
4,122
+2,524
+158% +$560K 0.61% 36
2025
Q4
$365K Hold
1,598
0.23% 89
2025
Q3
$370K Hold
1,598
0.24% 86
2025
Q2
$297K Buy
1,598
+273
+21% +$50.7K 0.22% 78
2025
Q1
$278K Buy
1,325
+15
+1% +$2.92K 0.26% 58
2024
Q4
$233K Buy
+1,310
New +$241K 0.22% 63

Other funds holding ABBV

SLT Holdings's ABBV Position: Q2 2026 in Review

SLT Holdings increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $105K and bringing the position to 4,609 shares worth $1.16M. The position accounts for 0.72% of the portfolio, ranked #36.

SLT Holdings first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SLT Holdings held 4,609 shares of AbbVie worth $1.16M as of Q2 2026.
  • SLT Holdings bought 487 AbbVie shares in Q2 2026, an estimated $105K.
  • AbbVie made up 0.72% of SLT Holdings's portfolio in Q2 2026, its #36 holding.
  • SLT Holdings first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SLT Holdings's 13F filing for Q2 2026, filed 17 Jul 2026.